Latest Data monitoring committees Stories
Enrollment in Worldwide Trial Continues as Planned REDMOND, Wash., Sept.
Phase III Trial Is Alive And Well; "Hint Of Failure" A Complete Fabrication; No Interim Analysis of Efficacy Done; 55 Patients' Positive Data Independently Collected. BETHESDA, Md., Aug.
BETHESDA, Md., March 7, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.